COVID-19: ECCMID 2023
COVID-19 Update: Independent Conference Coverage of ECCMID 2023

Released: May 05, 2023

Patrick W. G. Mallon
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI

Activity

Progress
1
Course Completed

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:

  • Treatment in special populations
    • REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
    • Remdesivir and readmission for COVID-19 in immunocompromised patients
    • Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
  •  
  • Management of patients with severe disease
    • RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
    • Real-world study of tocilizumab vs baricitinib for severe COVID-19
  • Novel antivirals
    • Ensitrelvir
    • Bemnifosbuvir
  • Novel vaccines
    • NB2155
    • AZD2816/AZD1222
    • qNIV/CoV2373
    • GRT-R910
    • NVX-CoV2373 in people with HIV